CRISPR Therapeutics (NASDAQ: CRSP) soared a few years ago, climbing more than 200% from the start of 2020 through early 2021, ...

Precise tumor diagnosis and treatment require the support of abundant molecular information. However, conventional molecular ...

AI therapeutics company built on causal biology, today announced the publication of research in Nature Communications validating its POSH (Pooled Optical Screening in Human cells) platform. The study ...

A new study from the Max Planck Institute for Evolutionary Anthropology examined how > 2,000 clinically approved drugs affect ...

In a new study, scientists at the Max Planck Institute for Evolutionary Anthropology in Leipzig analyzed the impact of more ...

Epithelial ovarian cancer (EOC) is an aggressive malignancy with limited therapeutic options. Poly(ADP-ribose) polymerase inhibitors (PARPi) have ...

Large-scale drug atlas uncovers new genome editing modulators and potential therapeutic strategies for DNA repair-deficient cancers ...

Epithelial ovarian cancer (EOC) is an aggressive malignancy with limited therapeutic options. Poly(ADP-ribose) polymerase ...

Researchers at Duke University used CRISPR technologies to discover previously unannotated stretches of DNA in the 'dark ...

Global CRISPR Technology Market OverviewThe global CRISPR technology market is poised for strong expansion, projected to grow at a robust CAGR of approximately 16% over the next five years. This ...

Programmable CRISPR tools are turning stem cell biology into something closer to software engineering, shrinking ...

Revvity's Dharmacon All-in-one lentiviral platform has expanded to include whole-genome library options for CRISPR knockout (CRISPRko), CRISPR interference (CRISPRi), and CRISPR activation (CRISPRa).